Barclays’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $386K | Buy |
85,712
+39,502
| +85% | +$178K | ﹤0.01% | 3176 |
|
|
2025
Q1 | $214K | Sell |
46,210
-24,531
| -35% | -$114K | ﹤0.01% | 3289 |
|
|
2024
Q4 | $491K | Buy |
70,741
+16,233
| +30% | +$113K | ﹤0.01% | 3064 |
|
|
2024
Q3 | $289K | Buy |
54,508
+43,499
| +395% | +$231K | ﹤0.01% | 3304 |
|
|
2024
Q2 | $41K | Sell |
11,009
-10,739
| -49% | -$40K | ﹤0.01% | 3748 |
|
|
2024
Q1 | $154K | Sell |
21,748
-39,520
| -65% | -$280K | ﹤0.01% | 3459 |
|
|
2023
Q4 | $346K | Buy |
61,268
+48,097
| +365% | +$272K | ﹤0.01% | 3223 |
|
|
2023
Q3 | $63K | Sell |
13,171
-464
| -3% | -$2.22K | ﹤0.01% | 3490 |
|
|
2023
Q2 | $94K | Sell |
13,635
-1,534
| -10% | -$10.6K | ﹤0.01% | 3423 |
|
|
2023
Q1 | $118K | Buy |
15,169
+7,181
| +90% | +$55.9K | ﹤0.01% | 3444 |
|
|
2022
Q4 | $61K | Buy |
7,988
+6,772
| +557% | +$51.7K | ﹤0.01% | 3699 |
|
|
2022
Q3 | $10K | Sell |
1,216
-224
| -16% | -$1.84K | ﹤0.01% | 4171 |
|
|
2022
Q2 | $14K | Sell |
1,440
-7,668
| -84% | -$74.6K | ﹤0.01% | 4209 |
|
|
2022
Q1 | $128K | Buy |
+9,108
| New | +$128K | ﹤0.01% | 3564 |
|